...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Keystone Talk, Tues 3/19
4
Feb 18, 2019 01:01PM
2
Feb 27, 2019 10:50PM

Keystone Symposium: Epigenetics and Human Disease (X5); March 17-21, 2019 in Banff, Alberta, Canada. 

Sarah Attwell will be presenting a short talk on Tuesday March 19th titled "The BET Inhibitor ZEN-3694 Blocks Multiple Tumor Immune Suppressive Factors and has the Potential to Increase the Efficacy of Anti-PD1 Treatment"

Good luck! Do they drive or fly to Banff?

BDAZ

Share
New Message
Please login to post a reply